Uroporphyrinogen III Synthase (UROS) is a critical cytosolic enzyme in the heme biosynthesis pathway. Mutations in the UROS gene lead to Congenital Erythropoietic Porphyria (CEP), also known as Günther's disease, a rare and debilitating metabolic disorder characterized by severe cutaneous photosensitivity, mutilating skin lesions, and hemolytic anemia. Emerging therapeutic strategies focus on pharmacological chaperones to stabilize unstable mutant UROS enzymes, gene therapies (AAV/Lentivirus) to restore enzyme activity, and enzyme replacement therapies (ERT).
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UROS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UROS WT / Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View UROS Products |
| Gene Delivery | UROS Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View UROS Products |
| Benchmark Ab | Anti-UROS Recombinant Antibody Recombinant positive control for expression validation. |
View UROS Products |
| Validator | UROS siRNA Set For knockdown verification and specificity controls. |
View UROS Products |
| Related Target A | HMBS (Hydroxymethylbilane Synthase) Immediate upstream enzyme in the heme pathway; critical for substrate accumulation studies. |
View HMBS Products |
| Related Target B | UROD (Uroporphyrinogen Decarboxylase) Immediate downstream enzyme; essential for pathway flux and selectivity profiling. |
View UROD Products |
| Related Target C | ALAS1 (5-Aminolevulinate Synthase 1) Rate-limiting enzyme of heme synthesis; primary target for substrate reduction therapies. |
View ALAS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Screening chaperones against highly unstable clinical mutants (e.g., C73R) | Sequence-verified mutant recombinant proteins engineered for maximum stability and high purity (>90%) |
| Distinguishing target-specific rescue from non-specific proteasome inhibition | Lentivirus-mediated expression of WT vs. mutant UROS combined with siRNA knockdown validation |
| Lack of reliable positive controls for expression assays | Recombinant sequence-defined benchmarker antibodies available for consistent assay baselines |
| Assay noise from bacterial endotoxin in enzymatic assays | Strictly endotoxin-controlled recombinant proteins (<1.0 EU/μg) to prevent cellular toxicity |
Live UROS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic pipeline for UROS is pivoting from palliative care toward curative genetic and molecular interventions. While hematopoietic stem cell transplantation (HSCT) remains the only curative option, it carries significant mortality risks. Consequently, the next wave of R&D is heavily focused on pharmacological chaperones that bind and rescue the folding of mutant UROS proteins (specifically the prevalent C73R mutation), alongside investigational gene addition therapies delivered via lentiviral vectors or AAVs to restore systemic enzymatic activity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pharmacological Chaperones | Academic Consortia, Rare Disease Biotechs | Congenital Erythropoietic Porphyria (CEP) | Thermal Shift Assays (DSF) requiring high-purity mutant UROS proteins (C73R, T228M) |
| Gene Therapy (AAV / Lentivirus) | Genethon, Vivet Therapeutics | Severe Infantile CEP | Lentivirus for stable cell line construction and expression validation of functional UROS |
| Enzyme Replacement Therapy (ERT) | Preclinical Research Groups | Systemic Porphyria Manifestations | High-purity, endotoxin-controlled WT recombinant UROS protein for systemic administration models |